Glioblastoma stem cells' circadian clocks ramp up the cells' metabolism, making them stronger, more resistant to treatment, and able to divide and multiply more rapidly. By targeting the stem cells with a small molecule drug, researchers found mice models lived longer and their tumors shrank.
Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer.
According to a new study, neural activity can stimulate the growth of high-grade glioma brain cancers.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Introducing VEGF-C into the cerebrospinal fluid of mouse models of glioblastoma, researchers noted increased levels of T cell response to the cancerous tumors. When combined with immune system checkpoint inhibitors, the VEGF-C treatment significantly extended the life span of the mice with glioblastoma brain cancer.
Researchers at MIT have developed a new drug delivering nanoparticle that is able to cross the blood-brain barrier. The nanoparticles carry two different drugs that can help shrink tumors and prevent them from growing back.